trial · primary record
Ifinatamab deruxtecan
Recurrent or Metastatic Solid Tumors
| Phase | Phase 1, Phase 2 |
|---|---|
| Status | RECRUITING |
| Sponsor | Unknown |
| Enrolment | 680 |
| Primary completion | 2028-07-25 |
| Primary endpoint | Objective Response Rate (ORR) as Assessed by Investigator |
| Registry ID | NCT06330064 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-10-28T02:32:15.989Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT06330064
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.